$ARGX News

argenx to Share New VYVGART Data for Autoimmune Diseases at EULAR

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1291

Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today

argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System

Evercore ISI Group Maintains Outperform on argenx, Raises Price Target to $1059

Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

argenx Announces FDA Approval Expanding VYVGART And VYVGART Hytrulo Label To Treat All Serotypes Of Generalized Myasthenia Gravis Based On ADAPT SERON Phase 3 Results

Guggenheim Maintains Buy on argenx, Raises Price Target to $1135

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1260

argenx Q1 EPS $5.52 Beats $5.42 Estimate, Sales $1.313B Miss $1.314B Estimate

Argenx Appoints Karen Massey CEO, Tim Van Hauwermeiren Board Chairperson

Argenx (ARGX) Outlook Improves on Autoimmune Pipeline Expansion

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

High Growth Tech Stocks in Europe with Promising Potential

A Look At argenx (ENXTBR:ARGX) Valuation After New VYVGART Data At The 2026 AAN Meeting

The Bull Case For argenx (ENXTBR:ARGX) Could Change Following New VYVGART Ocular MG Efficacy Data

Reported Earlier, Argenx Announced The Presentation Of New Data For Vyvgart In Myasthenia Gravis (MG) And Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) At The 2026 American Academy Of Neurology (AAN) Annual Meeting In Chicago From April 18-22, 2026

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

European Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading

Oppenheimer Maintains Outperform on argenx, Lowers Price Target to $1014